Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

13.87USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$13.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
275,429
52-wk High
$28.49
52-wk Low
$11.12

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Inc reports Q3 loss per share $0.38
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics Inc reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents, among others to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article

Cara therapeutics posts Q2 shr loss $0.48
Thursday, 4 Aug 2016 

Cara Therapeutics Inc : Q2 loss per share $0.48 . Cara therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.  Full Article

Cara Therapeutics resumes patient recruitment
Monday, 6 Jun 2016 

Cara Therapeutics Inc : Resumed patient recruitment after FDA removed clinical hold on CLIN3001 adaptive phase 3 trial of I.V. CR845 for postoperative pain . Study will continue as a three-arm trial comparing two doses of CR845 (1.0 and 0.5 ug/kg) to placebo . To provide updates on progress of trial later this year .Cara Therapeutics resumes patient recruitment for adaptive phase 3 trial of I.V. CR845 in postoperative pain.  Full Article

Cara therapeutics announces removal of FDA clinical hold on I.V. CR845 trial
Wednesday, 20 Apr 2016 

Cara therapeutics:Therapeutics announces removal of FDA clinical hold on clin3001 postoperative pain trial for i.v. Cr845.Received notice from fda that it has removed clinical hold on adaptive phase 3 trial of i.v. Cr845 for postoperative pain.Based on safety review study will continue as a three-arm trial testing two doses of cr845 (1 ug/kg and 0.5 ug/kg) versus placebo.  Full Article

BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection

* CARA THERAPEUTICS INITIATES PIVOTAL PHASE 3 EFFICACY TRIAL OF KORSUVA™ (CR845/DIFELIKEFALIN) INJECTION IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: